AGARWALEYE

Dr. Agarwal's Health Care Financial Results

₹484.05-0.58%
Market cap
₹15,335 crore
P/E
103.4
P/B
7.57
ROE
6.8%
Dividend yield
1.20%

For the year ended Mar 2023, Dr. Agarwal's Health Care reported revenue of ₹1,016 crore and net profit of ₹103 crore, against ₹1,328 crore and ₹95 crore a year earlier.

Dr. Agarwal's Health Care annual profit and loss

Financial years, newest first. TTM = trailing twelve months.

Dr. Agarwal's Health Care annual profit and loss (₹ crore)
ItemMar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue1,0161,3281,7052,0772,204
Expenses7359551,2251,4941,578
Operating profit282372479583626
Operating margin %28%28%28%28%28%
Other income234193225
Interest72961089089
Depreciation128170231276292
Profit before tax84141160249270
Tax %-23%32%31%32%31%
Net profit10395110168185
EPS (₹)2.982.632.644.204.68
Dividend payout %—————

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Dr. Agarwal's Health Care financial results — frequently asked questions

What is Dr. Agarwal's Health Care's annual revenue and net profit?

For the financial year ended Mar 2023, Dr. Agarwal's Health Care's revenue was ₹1,016 crore and net profit ₹103 crore; net profit rose 8.42% from ₹95 crore in Mar 2024.

How fast has Dr. Agarwal's Health Care grown over three years?

From Mar 2026 to Mar 2023, Dr. Agarwal's Health Care's revenue grew at a compound annual rate of -21.2% and net profit at -15.0%. Past growth does not indicate future results.

What is the EPS of Dr. Agarwal's Health Care?

Annual EPS for Mar 2023 was ₹2.98.

Are these figures consolidated or standalone?

They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.

Same Data For Peers

Trade Dr. Agarwal's Health Care With ATS

Track AGARWALEYE live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.